CL2021000844A1 - Compuestos de indolinona para uso como inhibidores de map4k1 - Google Patents

Compuestos de indolinona para uso como inhibidores de map4k1

Info

Publication number
CL2021000844A1
CL2021000844A1 CL2021000844A CL2021000844A CL2021000844A1 CL 2021000844 A1 CL2021000844 A1 CL 2021000844A1 CL 2021000844 A CL2021000844 A CL 2021000844A CL 2021000844 A CL2021000844 A CL 2021000844A CL 2021000844 A1 CL2021000844 A1 CL 2021000844A1
Authority
CL
Chile
Prior art keywords
map4k1
compounds
inhibitors
indolinone compounds
ring
Prior art date
Application number
CL2021000844A
Other languages
English (en)
Inventor
Sachin Sundarlal Chaudhari
Laxmikant Atmaram Gharat
Pravin Iyer
Sachin Vasantrao Dhone
Bharat Gangadhar Adik
Prashant Dilip Wadekar
Nagaraj Gowda
Malini Bajpai
Original Assignee
Ichnos Sciences S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences S A filed Critical Ichnos Sciences S A
Publication of CL2021000844A1 publication Critical patent/CL2021000844A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Abstract

La presente descripción se refiere a compuestos de fórmula (I) y sales farmacéuticamente aceptables de los mismos, en donde el anillo A, el anillo C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m y n son como se definen en la presente, que son útiles como inhibidores de MAP4K1, procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos y el uso de los compuestos o las composiciones en el tratamiento o prevención de diversas enfermedades, condiciones y/o trastornos mediados por MAP4K1.
CL2021000844A 2018-10-05 2021-04-05 Compuestos de indolinona para uso como inhibidores de map4k1 CL2021000844A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821037777 2018-10-05
IN201921009045 2019-03-08
IN201921024673 2019-06-21

Publications (1)

Publication Number Publication Date
CL2021000844A1 true CL2021000844A1 (es) 2021-11-12

Family

ID=68208286

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000844A CL2021000844A1 (es) 2018-10-05 2021-04-05 Compuestos de indolinona para uso como inhibidores de map4k1

Country Status (15)

Country Link
US (1) US20230009626A1 (es)
EP (1) EP3860976A1 (es)
JP (1) JP7101311B2 (es)
KR (1) KR20210068479A (es)
CN (1) CN113227049A (es)
AU (1) AU2019352075B2 (es)
BR (1) BR112021006319A2 (es)
CA (1) CA3115000A1 (es)
CL (1) CL2021000844A1 (es)
IL (1) IL281961A (es)
MX (1) MX2021003945A (es)
PE (1) PE20211054A1 (es)
SG (1) SG11202103459WA (es)
WO (2) WO2020070331A1 (es)
ZA (1) ZA202102259B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR20180100425A (el) * 2018-09-19 2020-05-11 Ηλιας Γεωργιου Τσιαβες Περιστρεφομενο κυπελλο μεταφορας για τα μπρατσα των καθρεπτων της μοτοσυκλετας
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
EP3972695A1 (en) * 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
WO2024017372A1 (zh) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 一种吲哚酮衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
CN109293551A (zh) * 2011-11-14 2019-02-01 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
AU2017322427B2 (en) * 2016-09-09 2021-12-23 Incyte Corporation Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer
US20180228786A1 (en) * 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof

Also Published As

Publication number Publication date
PE20211054A1 (es) 2021-06-07
SG11202103459WA (en) 2021-05-28
AU2019352075A1 (en) 2021-05-13
WO2020070332A1 (en) 2020-04-09
US20230009626A1 (en) 2023-01-12
JP7101311B2 (ja) 2022-07-14
AU2019352075B2 (en) 2022-07-21
WO2020070331A1 (en) 2020-04-09
KR20210068479A (ko) 2021-06-09
MX2021003945A (es) 2021-05-27
ZA202102259B (en) 2022-04-28
EP3860976A1 (en) 2021-08-11
CN113227049A (zh) 2021-08-06
BR112021006319A2 (pt) 2021-07-06
JP2022502455A (ja) 2022-01-11
IL281961A (en) 2021-05-31
CA3115000A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
UY37848A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
GT201600123A (es) Inhibidores de syk
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20150371A (es) Inhibidores de prmt5 y sus usos
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
ECSP18083519A (es) Inhibidores de bromodominios
UY37900A (es) Nuevos derivados de rapamicina
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
BR112019025049A2 (pt) Anéis 6- 5 fundidos como inibidores de c5a
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2017000827A1 (es) Inhibidores de aldosterona sintasa